,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
0,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
1,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
2,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
3,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
4,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
5,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
6,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
7,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
8,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
9,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
10,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
11,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
12,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
13,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
14,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
15,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
16,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
17,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
18,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
19,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
20,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
21,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
22,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
23,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
24,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
25,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
26,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
27,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
28,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
29,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
30,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
31,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
32,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
33,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Crizotinib,,"Active, not recruiting",NCT02034981,AcSe,PCD,2019Jun01,Yes,No,,4,NCT02034981,,,Overall Response Rate,246.0,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
34,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
35,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
36,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
37,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
38,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
39,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
40,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
41,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
42,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
43,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
44,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
45,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
46,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
47,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
48,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
49,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
50,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
51,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
52,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
53,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
54,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
55,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
56,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
57,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
58,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
59,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
60,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
61,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
62,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
63,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
64,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
65,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
66,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
67,ALK,ALK_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Ceritinib,,Withdrawn,NCT02289144,,PCD,2019Jan01,No,No,Development discontinued,4,NCT02289144,,,Time to progression,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
68,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
69,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
70,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
71,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
72,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
73,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
74,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
75,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
76,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
77,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
78,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
79,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
80,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
81,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
82,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
83,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
84,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
85,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
86,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
87,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
88,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
89,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
90,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
91,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
92,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
93,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
94,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
95,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
96,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
97,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
98,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
99,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
100,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
101,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Untreated,,Best overall response,26.0,26.0,,,42.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
102,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
103,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
104,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
105,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
106,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
107,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
108,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
109,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
110,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
111,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
112,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
113,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
114,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
115,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
116,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
117,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
118,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
119,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
120,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
121,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
122,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
123,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
124,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
125,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
126,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
127,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
128,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
129,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
130,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
131,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
132,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
133,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
134,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
135,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,HLX208,,Recruiting,NCT05102292,,ECD,2023May30,Yes,No,,4,NCT05102292,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Jan24,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
136,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
137,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
138,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
139,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
140,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
141,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
142,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
143,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
144,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
145,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
146,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
147,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
148,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
149,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
150,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
151,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
152,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
153,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
154,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
155,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
156,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
157,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
158,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
159,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
160,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
161,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
162,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
163,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
164,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
165,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
166,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
167,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
168,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
169,BRAF,BRAF_V600,,,p.V600X,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Vemurafenib,,Completed,NCT01286753,,PCD,2014Nov01,Yes,Yes,,4,NCT01286753,Previously-treated,,Best overall response,22.0,22.0,,,27.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2021May18,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
170,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
171,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
172,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
173,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
174,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
175,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
176,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
177,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
178,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
179,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
180,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
181,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
182,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
183,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
184,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
185,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
186,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
187,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
188,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
189,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
190,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
191,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
192,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
193,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
194,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
195,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
196,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
197,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
198,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
199,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
200,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
201,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
202,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
203,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT04739566,ANAPLAST-NEO,ECD,2024Jan22,Yes,No,,4,NCT04739566,,,Overall Response Rate,18.0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
204,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
205,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
206,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
207,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
208,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
209,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
210,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
211,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
212,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
213,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
214,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
215,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
216,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
217,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
218,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
219,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
220,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
221,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
222,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
223,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
224,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
225,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
226,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
227,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
228,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
229,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
230,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
231,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
232,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
233,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
234,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
235,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
236,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
237,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cemiplimab + Dabrafenib + Trametinib,,Recruiting,NCT04238624,,ECD,2024Jun20,Yes,No,,4,NCT04238624,,,Overall Response Rate,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Aug04,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
238,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
239,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
240,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
241,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
242,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
243,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
244,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
245,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
246,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
247,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
248,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
249,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
250,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
251,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
252,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
253,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
254,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
255,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
256,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
257,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
258,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
259,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
260,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
261,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
262,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
263,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
264,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
265,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
266,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
267,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
268,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
269,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
270,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
271,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Atezolizumab + Cobimetinib + Vemurafenib,,Recruiting,NCT03181100,,ECD,2023Jul27,Yes,No,,4,NCT03181100,,,Overall survival,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022May03,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
272,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
273,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
274,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
275,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
276,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
277,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
278,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
279,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
280,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
281,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
282,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
283,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
284,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
285,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
286,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
287,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
288,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
289,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
290,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
291,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
292,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
293,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
294,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
295,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
296,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
297,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
298,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
299,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
300,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
301,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
302,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
303,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
304,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
305,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Approved FDA,Dabrafenib + Trametinib,Required,Completed,NCT02034110,BRF117019,PCD,2021Dec10,Yes,Yes,,1,35026411,,,Overall Response Rate,36.0,36.0,,,56,,38.1-72.1,,,,,,6.7,,,,,,,,,,,,,14.5,,,,,,,,,,,,,,,,,COSO36286315,2022Dec14,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
306,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
307,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
308,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
309,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
310,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
311,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
312,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
313,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
314,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
315,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
316,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
317,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
318,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
319,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
320,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
321,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
322,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
323,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
324,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
325,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
326,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
327,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
328,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
329,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
330,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
331,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
332,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
333,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
334,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
335,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
336,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
337,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
338,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
339,BRAF,BRAF_V600E/K,56056643 + 56059110 + 56057713,,p.V600E + p.V600K,thyroid / carcinoma / anaplastic carcinoma,1,Phase 1,Dabrafenib + Intensity modulated radiation therapy + Trametinib,,Recruiting,NCT03975231,,ECD,2025Apr30,Yes,No,,4,NCT03975231,,,Maximum tolerated dose/toxicity,6.0,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov09,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
340,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
341,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
342,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
343,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
344,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
345,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
346,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
347,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
348,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
349,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
350,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
351,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
352,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
353,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
354,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
355,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
356,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
357,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
358,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
359,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
360,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
361,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
362,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
363,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
364,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
365,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
366,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
367,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
368,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
369,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
370,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
371,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
372,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
373,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 1,BI 3011441,,Completed,NCT04742556,,PCD,2022Oct13,Yes,No,,4,NCT04742556,,,Maximum tolerated dose/toxicity,15.0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
374,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
375,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
376,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
377,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
378,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
379,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
380,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
381,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
382,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
383,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
384,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
385,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
386,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
387,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
388,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
389,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
390,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
391,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
392,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
393,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
394,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
395,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
396,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
397,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
398,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
399,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
400,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
401,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
402,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
403,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
404,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
405,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
406,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
407,TP53,TP53_unspecified,,,,thyroid / carcinoma / anaplastic carcinoma,3,Phase 2,Cisplatin + Crolibulin,,Completed,NCT01240590,,PCD,2015Aug31,No,Yes,,2,10.1200/jco.2013.31.15_suppl.6074,,,Progression free survival,8.0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,1.0,,,,,,,,,COSO36286315,2022Nov28,COSO36286315,thyroid,NS,NS,NS,carcinoma,anaplastic_carcinoma,NS,NS
408,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
409,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
410,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
411,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
412,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
413,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
414,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
415,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Lapatinib,,"Active, not recruiting",NCT01947023,,ECD,2023Jul01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.6087,,,Maximum tolerated dose/toxicity,19.0,19.0,,,58,,,,,,,,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
416,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
417,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
418,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
419,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
420,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
421,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
422,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
423,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,CDX-3379 + Vemurafenib,,Completed,NCT02456701,,PCD,2016Oct13,Yes,Yes,Primary outcome met,1,35045748,,,Response rate,6.0,6.0,,,33.33,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,,COSO36284862,2022Dec13,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
424,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
425,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
426,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
427,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
428,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
429,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
430,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
431,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 1,Dabrafenib + Pazopanib,,Completed,NCT01713972,,PCD,2016Jul30,Expression confirmed,Yes,,2,10.1200/PO.17.00247,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
432,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
433,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
434,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
435,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
436,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
437,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
438,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
439,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
440,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
441,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
442,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
443,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
444,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
445,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
446,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
447,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Phase 2,Dabrafenib + Radioiodine + Trametinib,,"Active, not recruiting",NCT03244956,MERAIODE,ECD,2021Nov18,Yes,Yes,,2,10.1210/jendso/bvab048.1789,,,Overall Response Rate,21.0,21.0,,,38,,18-61,,,,,,,,,,,,,,,,90.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
448,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
449,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
450,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
451,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
452,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
453,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
454,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
455,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / NS,3,Unknown,Dabrafenib + Trametinib,,Recruiting,NCT05099068,PLANET,ECD,2025Sep15,Yes,No,,4,NCT05099068,,,"PFS, ORR",500.0,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jan24,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
456,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
457,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
458,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
459,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
460,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
461,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
462,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
463,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
464,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
465,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
466,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
467,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
468,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
469,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
470,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
471,BRAF,BRAF_V600E/M,56056643 + 56059110 + 56075762,,p.V600E + p.V600M,thyroid / carcinoma / NS,3,Phase 2,Binimetinib + Encorafenib + Nivolumab,,Recruiting,NCT04061980,,ECD,2023Jul30,Yes,No,,4,NCT04061980,,,Overall Response Rate,40.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
472,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
473,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
474,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
475,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
476,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
477,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
478,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
479,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib + Temsirolimus,,Completed,NCT01025453,,PCD,2018Jan16,No,Yes,,4,NCT01025453,Previously-treated,,Overall Response Rate,31.0,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.0,21.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
480,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
481,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
482,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
483,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
484,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
485,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
486,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
487,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Sorafenib,,Terminated,NCT00095693,,PCD,2005Aug01,Yes,Yes,Serious adverse events,2,10.1200/jco.2013.31.15_suppl.e17009,,,Overall Response Rate,25.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
488,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
489,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
490,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
491,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
492,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
493,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
494,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
495,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
496,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
497,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
498,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
499,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
500,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
501,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
502,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
503,BRAF,BRAF_unspecified,,,,thyroid / carcinoma / NS,2,Phase 3,Sorafenib,,Completed,NCT00984282 ,DECISION,PCD,2012Aug31,Comparison with wt,Yes,,1,24768112,Previously-treated,,Progression free survival,77.0,34.0,43.0,,,,,,,,,,20.5,9.4,0.46,0.24-0.9,0.02,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Nov03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
504,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
505,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
506,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
507,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
508,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
509,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
510,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
511,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Cabozantinib + Ipilimumab + Nivolumab,,"Active, not recruiting",NCT03914300,,ECD,2023Jan15,No,No,,4,NCT03914300,Previously-treated,,Overall Response Rate,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jun23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
512,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
513,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
514,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
515,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
516,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
517,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
518,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
519,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Lenvatinib + Pembrolizumab,,"Active, not recruiting",NCT02973997,,ECD,2022Oct08,No,No,,4,NCT02973997,,,Response rate,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug01,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
520,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
521,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
522,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
523,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
524,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
525,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
526,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
527,CD274,CD274_unspecified,,,,thyroid / carcinoma / NS,3,Retrospective/Meta-analysis,Lenvatinib + Pembrolizumab,,Unknown,,,,,Expression confirmed,Yes,Efficacy correlated with expression status,2,10.1089/thy.2020.0322,,,,6.0,6.0,,,66.0,,,,,,,,16.5,,,,,,,,,,,,,,,,,,,4.0,,1.0,,,,,,,,,COSO36284862,2022Dec12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
528,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
529,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
530,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
531,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
532,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
533,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
534,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
535,FGFR1,FGFR1_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Pazopanib,,Completed,NCT01813136,PAZOTHYR,PCD,2019Jan01,No,Yes,,2,10.1200/JCO.2020.38.15_suppl.6540,,,Time to progression,168.0,168.0,,,,,,,,,,,14.7,,,9.3-17.4,,,,,,,89.4,,,,,,,,,,,,,,,,,,,,COSO36284862,2021May18,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
536,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
537,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
538,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
539,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
540,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
541,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
542,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
543,KRAS,HRAS_G12 or HRAS_G13 or HRAS_Q61 or KRAS_G12 or KRAS_G13 or KRAS_Q61 or NRAS_G12 or NRAS_G13 or NRAS_Q61,,,,thyroid / carcinoma / NS,3,Phase 2,Radioiodine + Trametinib,,"Active, not recruiting",NCT02152995,Cohort A,PCD,2021Aug25,Yes,Yes,,2,10.1200/JCO.2022.40.16_suppl.6089,,,"PFS, ORR",14.0,14.0,,,57,,,,,,,,,,,,,,,,,,78.0,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
544,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
545,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
546,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
547,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
548,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
549,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
550,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
551,HRAS,HRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Tipifarnib,,Completed,NCT02383927,,ECD,2020Nov30,Yes,No,,4,NCT02383927,Previously-treated,,Overall Response Rate,63.0,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug12,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
552,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
553,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
554,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
555,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
556,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
557,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
558,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
559,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Everolimus + Sorafenib,,"Active, not recruiting",NCT01263951,,PCD,2021Feb01,No,Yes,,2,10.1200/jco.2015.33.15_suppl.6072,,,Progression free survival,13.0,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,18.0,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
560,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
561,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
562,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
563,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
564,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
565,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
566,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
567,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Trametinib,,Recruiting,NCT05182931,I-FIRST,ECD,2024Dec30,Yes,No,,4,NCT05182931,Previously-treated,,Progression free survival,80.0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Aug04,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
568,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
569,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
570,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
571,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
572,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
573,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
574,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
575,NRAS,NRAS_unspecified,,,,thyroid / carcinoma / NS,3,Phase 3,Radioiodine + Selumetinib,,Terminated,NCT01843062,ASTRA,PCD,2018May18,No,Yes,Primary outcome not met,4,NCT01843062,,,Complete remission,233.0,155.0,78.0,Placebo + Radioiodine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
576,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
577,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
578,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
579,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
580,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
581,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
582,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
583,NTRK1,NTRK1_fusions,,,,thyroid / carcinoma / NS,3,Phase 1,Taletrectinib,,Completed,NCT02279433,,PCD,2019Mar01,Yes,Yes,,2,10.1200/JCO.2018.36.15_suppl.2514,Previously-treated,,Clinical activity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
584,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
585,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
586,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
587,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
588,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
589,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
590,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
591,NTRK1,NTRK1_fusions or NTRK2_fusions or NTRK3_fusions,,,,thyroid / carcinoma / NS,3,Phase 2,Larotrectinib,,Recruiting,NCT02576431,NAVIGATE Arm 2,ECD,2023Aug15,Yes,No,,4,NCT02576431,,,Best overall response,204.0,204.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022Jul15,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
592,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
593,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
594,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
595,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
596,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
597,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
598,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
599,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,9.0,9.0,,,89,,52-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan19,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
600,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
601,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
602,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
603,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
604,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
605,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
606,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
607,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,8.0,8.0,,,100,,63-100,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
608,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
609,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
610,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
611,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
612,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
613,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
614,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
615,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,19.0,19.0,,,79,,54-94,,18.4,,7.6-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan23,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
616,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
617,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
618,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
619,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
620,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
621,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
622,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
623,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,1.0,1.0,,,100,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36284862,2022Nov28,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
624,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
625,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
626,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
627,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
628,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
629,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
630,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
631,RET,RET_fusions,,,,thyroid / carcinoma / NS,1,Phase 2,Radioiodine + Selpercatinib,,Not yet recruiting,NCT05668962,,ECD,2024Mar01,Yes,No,,4,NCT05668962,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2023Jan09,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
632,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
633,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
634,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
635,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
636,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
637,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
638,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
639,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 1,Alectinib,,Terminated,NCT03131206,,PCD,2018Nov08,Yes,Yes,"Slow accrual, Lack of efficacy",4,NCT03131206,,,Overall Response Rate,5.0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2021Oct29,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
640,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
641,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
642,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
643,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
644,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
645,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
646,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
647,RET,RET_unspecified,,,,thyroid / carcinoma / NS,3,Phase 2,Selpercatinib,,Recruiting,NCT04759911,,ECD,2024Sep10,Yes,No,,4,NCT04759911,,,Overall Response Rate,30.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36284862,2022May03,COSO36284862,thyroid,NS,NS,NS,carcinoma,NS,NS,NS
648,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
649,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
650,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
651,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
652,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
653,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
654,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
655,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
656,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
657,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
658,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
659,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
660,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
661,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
662,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
663,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
664,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
665,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
666,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
667,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
668,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
669,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
670,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
671,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
672,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
673,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
674,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
675,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
676,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
677,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
678,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
679,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
680,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
681,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
682,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
683,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
684,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
685,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
686,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
687,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
688,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
689,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
690,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
691,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
692,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
693,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
694,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
695,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
696,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
697,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
698,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
699,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
700,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
701,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
702,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
703,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
704,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
705,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
706,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
707,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
708,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
709,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
710,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
711,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
712,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
713,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
714,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
715,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
716,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
717,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
718,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
719,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
720,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
721,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
722,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
723,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,Agerafenib,,Completed,NCT01877811,,PCD,2018Dec01,No,Yes,,2,10.1200/JCO.2016.34.15_suppl.2574,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286294,2022Nov28,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
724,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
725,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
726,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
727,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
728,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
729,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
730,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
731,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
732,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
733,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
734,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
735,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
736,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
737,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
738,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
739,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
740,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
741,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
742,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
743,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
744,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
745,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
746,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
747,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
748,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
749,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
750,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
751,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
752,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
753,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
754,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
755,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
756,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
757,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
758,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
759,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
760,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
761,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
762,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
763,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
764,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
765,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
766,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
767,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
768,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
769,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
770,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
771,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
772,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
773,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
774,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
775,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
776,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
777,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
778,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
779,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
780,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
781,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
782,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
783,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
784,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
785,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
786,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
787,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
788,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
789,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
790,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
791,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
792,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
793,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
794,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
795,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
796,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
797,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
798,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
799,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 1,XL281,,Unknown,,,,,Yes,Yes,,2,10.1200/jco.2009.27.15s.3513,,,Unknown,2.0,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,,,,,,,,,COSO36286294,2021May18,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
800,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
801,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
802,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
803,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
804,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
805,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
806,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
807,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
808,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
809,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
810,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
811,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
812,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
813,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
814,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
815,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
816,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
817,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
818,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
819,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
820,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
821,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
822,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
823,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
824,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
825,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
826,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
827,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
828,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
829,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
830,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
831,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
832,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
833,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
834,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
835,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
836,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
837,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
838,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
839,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
840,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
841,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
842,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
843,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
844,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
845,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
846,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
847,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
848,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
849,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
850,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
851,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
852,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
853,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
854,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
855,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
856,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
857,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
858,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
859,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
860,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
861,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
862,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
863,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
864,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
865,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
866,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
867,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
868,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
869,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
870,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
871,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
872,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
873,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
874,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
875,BRAF,BRAF_V600E,56056643 + 56059110,,p.V600E,thyroid / carcinoma / papillary carcinoma,3,Phase 2,Vemurafenib,,"Active, not recruiting",NCT01709292,,ECD,2022Sep30,Yes,No,,4,NCT01709292,,,Marker phosphorylation,24.0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286294,2022May03,COSO36286294,thyroid,NS,NS,NS,carcinoma,papillary_carcinoma,NS,NS
876,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
877,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
878,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
879,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
880,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
881,RET,KIF5B-RET_fusion COSF1231,,,,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
882,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
883,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
884,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
885,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
886,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
887,RET,RET V804M or RET_M918T,60685905 + 60710027,,p.M918T + p.V804M,thyroid / carcinoma / medullary carcinoma,4,Case study,Selpercatinib,,Unknown,,,,,Yes,Yes,,1,29912274,Previously-treated,,Unknown,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
888,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
889,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
890,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
891,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
892,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
893,RET,RET_C634R,60686093,,p.C634R,thyroid / carcinoma / medullary carcinoma,3,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
894,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
895,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
896,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
897,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
898,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
899,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Sorafenib,,"Active, not recruiting",NCT00390325,,PCD,2017Jan30,Yes,Yes,,1,20368568,,,Overall Response Rate,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,8.0,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
900,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
901,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
902,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
903,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
904,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
905,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 2,Vandetanib,,Completed,NCT00514046,,PCD,2019Dec10,Yes,Yes,,1,29187393,,Pediatric,Overall Response Rate,16.0,16.0,,,59,,,,,,,,80.4,,,,,,,,,,,,,,,,,,,,10.0,6.0,,,,,,,,,COSO36286327,2023Jan25,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
906,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
907,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
908,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
909,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
910,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
911,RET,RET_M918T,60685905,,p.M918T,thyroid / carcinoma / medullary carcinoma,2,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,Yes,Yes,,1,27525386,,,Progression free survival,126.0,81.0,45.0,,,,,,,,,,14.08,3.92,0.15,0.08-0.28,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
912,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
913,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
914,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
915,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
916,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
917,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,60,,44-73,,,,15.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
918,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
919,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
920,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
921,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
922,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
923,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Untreated,,Overall Response Rate,88.0,88.0,,,73,,62-82,,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
924,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
925,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
926,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
927,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
928,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
929,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Selpercatinib,Required,Recruiting,NCT03157128,LIBRETTO-001,ECD,2024Mar21,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf,Previously-treated,,Overall Response Rate,55.0,55.0,,,69,,55-81,,,,19.1-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan23,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
930,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
931,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
932,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
933,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
934,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
935,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Approved FDA,Pralsetinib,Required,"Active, not recruiting",NCT03037385,ARROW,ECD,2023Dec31,Yes,Yes,,7,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213721s007lbl.pdf,,,Overall Response Rate,29.0,29.0,,,66,,46-82,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2023Jan19,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
936,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
937,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
938,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
939,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
940,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
941,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 1,DS-5010 ,,"Active, not recruiting",NCT03780517,,ECD,2023Apr30,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.3008,,,Maximum tolerated dose/toxicity,16.0,16.0,,,44,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
942,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
943,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
944,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
945,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
946,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
947,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Sunitinib,,"Active, not recruiting",NCT00381641,,PCD,2016Dec31,No,Yes,,4,NCT00381641,,,Overall Response Rate,25.0,25.0,,,28.0,,,,,,,,,,,,,19.3,,,7.7-34.6,,,,,65.4,,,27.0-69.5,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
948,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
949,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
950,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
951,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
952,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
953,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Selpercatinib,,"Active, not recruiting",NCT04280081,LIBRETTO-321,PCD,2021Mar25,Yes,Yes,,4,NCT04280081,,,Overall Response Rate,26.0,26.0,,,57.7,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
954,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
955,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
956,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
957,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
958,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
959,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Withdrawn,NCT03838692,,PCD,2021Jun14,No,No,,4,NCT03838692,,,Overall Response Rate,0.0,0.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022May03,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
960,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
961,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
962,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
963,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
964,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
965,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 2,Ponatinib,,Terminated,NCT01838642,,PCD,2015Dec01,Comparison with wt,Yes,Changed business priorities,4,NCT01838642,,,Overall Response Rate,3.0,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2021May18,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
966,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
967,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
968,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
969,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
970,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
971,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Cabozantinib,,Completed,NCT00704730,EXAM,PCD,2011Oct01,No,Yes,,1,27525386,,,Progression free survival,169.0,107.0,62.0,,,,,,,,,,13.85,4.62,0.23,0.14-0.38,<0.0001,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
972,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
973,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
974,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
975,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
976,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
977,RET,RET_unspecified,,,,thyroid / carcinoma / medullary carcinoma,1,Phase 3,Pralsetinib,,Not yet recruiting,NCT04760288,AcceleRET-MTC,ECD,2027Oct06,Yes,No,,4,NCT04760288,Previously-treated,,Progression free survival,198.0,,,Cabozantinib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO36286327,2022Nov28,COSO36286327,thyroid,NS,NS,NS,carcinoma,medullary_carcinoma,NS,NS
